Nitric oxide/cGMP signalling mediates the cardioprotective action of adrenomedullin in reperfused myocardium.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Steinkopff Country of Publication: Germany NLM ID: 0360342 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1435-1803 (Electronic) Linking ISSN: 03008428 NLM ISO Abbreviation: Basic Res Cardiol Subsets: MEDLINE
    • Publication Information:
      Original Publication: Darmstadt, Steinkopff.
    • Subject Terms:
      Adrenomedullin/*metabolism ; Cyclic GMP/*metabolism ; Guanylate Cyclase/*metabolism ; Myocardial Infarction/*metabolism ; Myocardial Reperfusion Injury/*metabolism ; Nitric Oxide/*biosynthesis; Adrenomedullin/administration & dosage ; Animals ; In Vitro Techniques ; Male ; Mice ; Myocardial Infarction/etiology ; Myocardial Infarction/pathology ; Myocardial Infarction/prevention & control ; Myocardial Reperfusion Injury/complications ; Myocardial Reperfusion Injury/pathology ; Myocardial Reperfusion Injury/prevention & control ; Myocardium/pathology ; Signal Transduction
    • Abstract:
      We demonstrated previously that adrenomedullin (AM), when given during early reperfusion, limited infarct size in rat heart. The present study was undertaken to provide direct evidence of the NO-dependency of AM's cardioprotective action by assessing NO biosynthesis and involvement of the soluble guanylyl cyclase (sGC) pathway. Perfused hearts from male CD-1 mice were subjected to 30-min left coronary occlusion and 60-min reperfusion. Infarct size was determined by tetrazolium staining. AM 10 nM was administered from 20 min after coronary occlusion until 10 min after reperfusion. Coronary effluent was analysed for NO2- and NO3-, and myocardial samples were analysed for NO2-, NO3-, nitroso-adducts and cGMP concentration. To examine the role of NO/sGC signalling in the infarct-limiting action of AM, further hearts received the sGC inhibitor ODQ 2 microM. AM treatment stimulated NO synthesis, indicated by increased NO2- efflux in coronary effluent throughout reperfusion (summarised as area under curve, AM 29.2 +/- 3.9 vs. control 14.4 +/- 2.8 micromol min2 mL(-1), P < 0.05). AM limited infarct size (35.4 +/- 2.7 vs. 12.2 +/- 2.3%, P < 0.01), associated with a 2.45-fold increase (P < 0.05) in myocardial cGMP concentration at 10 min after reperfusion. ODQ abolished the infarct size-limiting effect of AM (28.9 +/- 4.3%). These data provide the first evidence that AM increases NO bioavailability in intact murine myocardium and confirm that the NO/sGC/cGMP pathway is central to the cytoprotective action of AM against ischaemia-reperfusion injury.
    • Grant Information:
      PG/03/030 United Kingdom British Heart Foundation
    • Accession Number:
      148498-78-6 (Adrenomedullin)
      31C4KY9ESH (Nitric Oxide)
      EC 4.6.1.2 (Guanylate Cyclase)
      H2D2X058MU (Cyclic GMP)
    • Publication Date:
      Date Created: 20090829 Date Completed: 20100331 Latest Revision: 20141120
    • Publication Date:
      20231215
    • Accession Number:
      10.1007/s00395-009-0058-7
    • Accession Number:
      19714395